As of March 7, 2024, Johnson & Johnson completed its acquisition of Ambrx. Visit the Johnson & Johnson website

The Pioneer and Leader in Next Generation Antibody Drug Conjugates (ADCs)

Focused Oncology Portfolio

We are advancing enhanced antibody-drug conjugate, immuno-oncology conjugate and bispecific candidates as potential treatments for cancer.

Expanded Genetic Code Technology Platform

We incorporate synthetic amino acids into proteins within living cells. The result? Product candidates designed for highly stable, site-specific conjugation, overcoming the inherent limitations of conventional conjugation approaches.

ARX517 KOL Event at ESMO 2023

Featuring preliminary safety, efficacy, and PK data from APEX-01, a first-in-human study evaluating ARX517 in advanced prostate cancer patients presented at ESMO.

Sunday, October 22, 2023